Cytokinetics(US:CYTK) Globenewswireยท2025-10-25 14:50Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to investor losses during the class period from December 27, 2023, to May 6, 2025 [7]. Allegation Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, stating it would occur in the second half of 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [7]. - On May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, which misled investors about the regulatory timeline [7]. Next Steps - Investors who purchased Cytokinetics shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].